PROGEN Prostatype Genomics AB (publ)

STO · SE · Healthcare · Diagnostics & Research · prostatypegenomics.com

0.0944SEK+1.29%Mkt Cap: 1.40M $P/E: —3d ago

Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers a Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, glea…

Industry Peers

Diagnostics & Research

Screen all

TMO

Thermo Fisher Scientific Inc Common Stock

$242.11BUSDP/E 35.5

DHR

Danaher Corporation Common Stock

$150.48BUSDP/E 38.2

NTRA

Natera, Inc. - Common Stock

Agilent Technologies, Inc. Common Stock

$47.30BUSDP/E 33.1

IQV

IQVIA Holdings, Inc. Common Stock

$42.50BUSDP/E 32.2

WAT

Waters Corporation Common Stock

$41.75BUSDP/E 107.4

ILMN

Illumina, Inc. - Common Stock

$41.23BUSDP/E 50.8

IDXX

IDEXX Laboratories, Inc. - Common Stock

$40.89BUSDP/E 36.4

MTD

Mettler-Toledo International, Inc. Common Stock

$29.78BUSDP/E 34.0

DGX

Quest Diagnostics Incorporated Common Stock

$25.75BUSDP/E 25.0

Labcorp Holdings Inc. Common Stock

$25.02BUSDP/E 25.5

Guardant Health, Inc. - Common Stock

$23.86BUSD

RVTY

Revvity, Inc. Common Stock

$16.91BUSDP/E 72.5

MEDP

Medpace Holdings, Inc. - Common Stock

$16.73BUSDP/E 35.2

ERF

Eurofins Scientific SE

$14.05BUSDP/E 26.2

CRL

Charles River Laboratories International, Inc. Common Stock

$13.85BUSD

ICLR

ICON plc - Ordinary Shares

Qiagen N.V. Common Shares

$9.24BUSDP/E 22.7

Key Statistics

Company

Market Cap1.40M USD

Enterprise Value5.02M USD

Revenue (TTM)77.00K USD

Gross Profit56.82K USD

Net Income (TTM)-4.26M USD

Revenue/Share0.01 SEK

Last Price0.0944 SEK

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees7

CountrySE

SectorHealthcare

IndustryDiagnostics & Research

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-0.94

PEG—

EV/EBITDA-1.54

EV/Revenue65.19

P/S18.24

P/B0.85

EPS (TTM)-0.26

EPS (Forward)-0.10

52W Range

0.08800% of range2.280

52W High2.280 SEK

52W Low0.0880 SEK

Profitability

Gross Margin100.00%

Oper. Margin-4066.96%

EBITDA Margin0.00%

Profit Margin-7492.09%

ROE-167.75%

ROA-87.50%

Growth

Revenue Growth85.80%

Earnings Growth—

Cash Flow & Leverage

Operating CF-2.28M USD

CapEx (TTM)1.29M USD

FCF Margin-879.44%

FCF Yield-48.21%

Net Debt-37.50K USD

Net Debt/EBITDA0.01

Balance Sheet

Debt/Equity0.20

Current Ratio0.04

Quick Ratio0.04

Book Value/Sh0.11 SEK

Cash/Share0.0010 SEK

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 SEK

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Splits

Last Split1:1000

Split DateOct 31, 2024

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.155.57M

Float541.18M

Insiders34.63%

Institutions4.18%

Technical

SMA 500.1390 (-32.1%)

SMA 2000.6263 (-84.9%)

Beta1.40

S&P 52W Chg14.58%

Avg Vol (30d)10.77M

Avg Vol (10d)12.43M

Technical Indicators

RSI (14)30.8

MACD-0.0179

MACD Signal-0.0133

MACD Hist.-0.0046

BB Upper0.1958 SEK

BB Middle0.1378 SEK

BB Lower0.0798 SEK

BB Width84.23%

ATR (14)0.0197 SEK

Vol Ratio (20d)1.03x